Plain-English translation of NCT07610395 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called vapendavir to see if it can help people with COPD (a chronic lung disease) recover faster and feel better when they catch a cold caused by rhinovirus. Researchers want to find the right dose of this medication by comparing it to a placebo (a dummy pill). The goal is to understand if this treatment can shorten how long cold symptoms last or make them less severe.
People with COPD often have a much harder time recovering from common colds, and their symptoms can be more serious and longer-lasting. Right now, there is no specific treatment for rhinovirus infections in this population. This medication is being tested to see if it could become a new tool to help these patients feel better and recover more quickly.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new medication at a high dose, the medication at a lower dose, or a placebo (dummy pill). You will take your assigned treatment once at the study clinic on Day 1, then continue taking it at home every day for 7 doses total, always with food. Throughout the study, you will use a mobile app to track your daily cold symptoms and perform nasal swabs at home. The study lasts several weeks, with regular check-ins to monitor how you are doing and whether the treatment is helping.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States